97 related articles for article (PubMed ID: 18455056)
1. [HIV tropism assays when first CCR5-antagonist becomes available].
Soulié C; Calvez V
Med Mal Infect; 2008 Mar; 38 Suppl 1():S7-11. PubMed ID: 18455056
[TBL] [Abstract][Full Text] [Related]
2. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
4. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two genotypic algorithms to determine HIV-1 tropism.
Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
Visseaux B; Hurtado-Nedelec M; Charpentier C; Collin G; Storto A; Matheron S; Larrouy L; Damond F; Brun-Vézinet F; Descamps D;
J Infect Dis; 2012 Jan; 205(1):111-20. PubMed ID: 22140264
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of HIV coreceptor tropism.
Hoffmann C
Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
[TBL] [Abstract][Full Text] [Related]
9. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.
Raymond S; Delobel P; Mavigner M; Cazabat M; Souyris C; Sandres-Sauné K; Cuzin L; Marchou B; Massip P; Izopet J
AIDS; 2008 Sep; 22(14):F11-6. PubMed ID: 18753930
[TBL] [Abstract][Full Text] [Related]
10. Phenotyping methods for determining HIV tropism and applications in clinical settings.
Raymond S; Delobel P; Izopet J
Curr Opin HIV AIDS; 2012 Sep; 7(5):463-9. PubMed ID: 22832712
[TBL] [Abstract][Full Text] [Related]
11. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.
Low AJ; Dong W; Chan D; Sing T; Swanstrom R; Jensen M; Pillai S; Good B; Harrigan PR
AIDS; 2007 Sep; 21(14):F17-24. PubMed ID: 17721088
[TBL] [Abstract][Full Text] [Related]
12. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools.
Chueca N; Garrido C; Alvarez M; Poveda E; de Dios Luna J; Zahonero N; Hernández-Quero J; Soriano V; Maroto C; de Mendoza C; García F
J Med Virol; 2009 May; 81(5):763-7. PubMed ID: 19319937
[TBL] [Abstract][Full Text] [Related]
13. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.
Poveda E; Seclén E; González Mdel M; García F; Chueca N; Aguilera A; Rodríguez JJ; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2009 May; 63(5):1006-10. PubMed ID: 19261623
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
Garrido C; Roulet V; Chueca N; Poveda E; Aguilera A; Skrabal K; Zahonero N; Carlos S; García F; Faudon JL; Soriano V; de Mendoza C
J Clin Microbiol; 2008 Mar; 46(3):887-91. PubMed ID: 18199789
[TBL] [Abstract][Full Text] [Related]
15. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Seclén E; Garrido C; González Mdel M; González-Lahoz J; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1486-92. PubMed ID: 20427374
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals.
Braun P; Wiesmann F
Eur J Med Res; 2007 Oct; 12(9):463-72. PubMed ID: 17933728
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
[TBL] [Abstract][Full Text] [Related]
18. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors.
Arastéh K; Stocker H
Eur J Med Res; 2007 Oct; 12(9):397-402. PubMed ID: 17933720
[TBL] [Abstract][Full Text] [Related]
19. Comment on: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Raymond S; Delobel P; Izopet J
J Antimicrob Chemother; 2010 Sep; 65(9):2056-7; author reply 2058-9. PubMed ID: 20554569
[No Abstract] [Full Text] [Related]
20. Determination of HIV-1 coreceptor tropism in clinical practise.
Foeglein A; Walter H
Eur J Med Res; 2007 Oct; 12(9):473-82. PubMed ID: 17933729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
